Ara
Toplam kayıt 3, listelenen: 1-3
The Impact Of Jak1/Jak2 Inhibitor Ruxolitinib On The Spleen Size And Symptom Burden In Myeloproliferative Diseases
(Akad Doktorlar Yayınevi, 2016)
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
(Akad Doktorlar Yayınevi, 2012)
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose ...
Hacettepe Dahiliye Ders Kitabı 2
(Hacettepe Üniversitesi, 2020)
Ondokuzuncu yüzyılın tıp literatürü, korku filmi gibidir. Hekimlerin, ellerine geçirdikleri her şeyi,
akıllarına gelen her yöntemi tedavi için kullandıkları görülür. Bilgiye değil, kulaktan dolma duyumlara
dayanan, “içten ...